Skip to content

Caffeine/Glucose and Multi-tasking

An investigation into the effects of two doses of glucose alone and a single dose of caffeine-glucose in combination on cognitive performance, fatigue and mood associated with extended multi-tasking in healthy adults aged 18-55 years

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12613000247774
Enrollment
160
Registered
2013-03-01
Start date
2011-02-01
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This investigation is a single centre, double blind, parallel groups design assessing the effects of two doses of glucose alone and a dose of caffeine- glucose combination on cognitive performance, fatigue, stress and mood associated with extended multi-tasking. Using a randomised double blind crossover design, up to 160 healthy frequent caffeine consumers will attend 2 sessions (1 practice and 1 test session). During the practice session participants will complete a battery of cognitive tasks, mood and fatigue ratings. During the test session they will complete a battery of cognitive tasks, mood and fatigue ratings once before and once after receiving one drink corresponding to: 1. Placebo - Britvic Tango Orange Sparkling Drink, Diet sugar free fizzy orange drink 2. 25g Glucose - Lucozade energy (International) diluted with Tango orange 3. 60g Glucose - Lucozade energy (International i.e. outside UK) 4. 60g Glucose/40mg Caffeine - Lucozade energy (UK)

Interventions

Using a randomised double blind crossover design, up to 160 healthy frequent caffeine consumers will attend 2 sessions (1 practice and 1 test session). During the practice session participants will complete a battery of cognitive tasks, mood and fatigue ratings. During the test session they will complete a battery of cognitive tasks, mood and fatigue ratings once before and once after receiving either one 330ml drink corresponding to: 1. Placebo - Britvic Tango Orange Sparkling Drink, Diet su

Using a randomised double blind crossover design, up to 160 healthy frequent caffeine consumers will attend 2 sessions (1 practice and 1 test session). During the practice session participants will complete a battery of cognitive tasks, mood and fatigue ratings. During the test session they will complete a battery of cognitive tasks, mood and fatigue ratings once before and once after receiving either one 330ml drink corresponding to: 1. Placebo - Britvic Tango Orange Sparkling Drink, Diet sugar free fizzy orange drink 2. 25g Glucose - Lucozade energy (International) diluted with Tango orange 3. 60g Glucose - Lucozade energy (International i.e. outside UK) 4. 60g Glucose/40mg Caffeine - Lucozade energy (UK)

Sponsors

GlaxoSmithKline Nutritional Healthcare Future Group
Lead SponsorCommercial sector/Industry

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Caregiver)

Eligibility

Sex/Gender
All
Age
18 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

1. Male or female. 2. Aged 18-55 years. 3. Willing and able to provide written informed consent. 4. Understands and is willing and able to comply with all study procedures. 5. Are in good general health with no history of psychiatric disease. 6. Regular caffeine consumers (between 1-4 cups of coffee per day)

Exclusion criteria

1. Females who are pregnant, breast-feeding and/or not using a medically approved form of contraception. 2. Any significant concurrent illness including any bleeding disorders, heart conditions, diabetes, glaucoma, high blood pressure or osteoporosis. 3. Individuals who suffer from Diabetes Mellitus. 4. Any known or suspected food allergies (this would cover all ingredients in the investigational product). 5. Susceptible to any unwanted side-effects of caffeine, such as reduction in sleep quality. 6. Smokers and users of recreational drugs (except alcohol and other food grade actives) 7. Have participated in any other study involving an investigational product in the last 4 weeks. 8. Those diagnosed with Phenyketonuria (PKU).

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026